Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Lyell Immunopharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +5 vs. Q4 2022
- Shares held
- 117.8M
- +1.11M (+0.9%) vs. Q4 2022
- Total value
- $277.9M
- −$126.9M (−31.3%) vs. Q4 2022
- New holders
- 20
- 30 more added
- Sold out
- 15
- 24 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LYEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 87 | $178.0M |
| Q1 2026 | 74 | $251.1M |
| Q4 2025 | 69 | $371.9M |
| Q3 2025 | 59 | $164.9M |
| Q2 2025 | 69 | $81.9M |
| Q1 2025 | 112 | $81.8M |
| Q4 2024 | 105 | $95.9M |
| Q3 2024 | 117 | $176.6M |
| Q2 2024 | 120 | $194.2M |
| Q1 2024 | 127 | $296.8M |
| Q4 2023 | 119 | $255.2M |
| Q3 2023 | 106 | $180.1M |
| Q2 2023 | 99 | $388.7M |
| Q1 2023 | 99 | $277.9M |
| Q4 2022 | 95 | $404.8M |
| Q3 2022 | 93 | $823.5M |
| Q2 2022 | 75 | $688.6M |
| Q1 2022 | 79 | $502.7M |
| Q4 2021 | 77 | $662.2M |
| Q3 2021 | 62 | $1.22B |
| Q2 2021 | 52 | $1.29B |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Lyell Immunopharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −513,200−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −307,389−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −124,795−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −58,781−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −27,051−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −23,284−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −22,558−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −16,084−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −7,800−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −4,219−100.0% | Sold out |
| Comerica Securities,inc. | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| SJS Investment Consulting Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −144−100.0% | Sold out |
| Sargent Bickham Lagudis LLC | – | – | – | – | Not filed |